Wire · opportunities
Ivonescimab beats durvalumab in biliary tract cancer Phase III trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
Ivonescimab combined with chemotherapy demonstrated a statistically significant overall survival benefit over durvalumab plus chemotherapy in a Phase III biliary tract cancer trial conducted in China, challenging the current first-line standard. Results will be presented at ESMO 2026, with potential impact on regulatory filings beyond China.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a rare chance as an oncology founder to position a PD-1/VEGF bispecific drug against an established FDA-approved standard. If the survival gap is meaningful, regulators outside China could open their doors to your filings soon.
◆ Coverage
1 source · 22 Sep 2026
◆ Related on Wire
◆ Topics